Retrospective analysis shows similar outcomes in MRD-negative AML and ALL with non-myeloablative conditioning, suggesting reduced toxicity with PTCY-based GVHD prophylaxis.
Key Points
This research aims to compare outcomes of myeloablative and non-myeloablative conditioning in MRD-negative AML and ALL.
Conducted a single-center retrospective study of adults with AML or ALL undergoing allo-HSCT.
Patients were MRD-negative and evaluated using multi-parametric flow cytometry or quantitative PCR.
Conditioning regimens were categorized into myeloablative, reduced intensity, and non-myeloablative.
Overall survival was 75.6% at 1 year and 73.8% at 4 years, with no significant difference between AML and ALL.
The incidence of acute graft-versus-host disease was 22% at 100 days and 33% at 6 months.
Non-myeloablative conditioning showed comparable overall survival and GVHD outcomes to myeloablative regimens.